Evidence map›Paper›PMID 33723317›Full record

ArticleScientific reports2021

Penile secondary lesions: a rare entity detected by PET/CT.

Tima Davidson, Liran Domachevsky, Yogev Giladi, Eddie Fridman, Zohar Dotan, Barak Rosenzweig, Raya Leibowitz, Jennifer Ben Shimol

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Case Report:Frontiers in oncology · 2022
    Article
  4. Case Report:Frontiers in oncology · 2021
    Article
  5. An unusual, delayed, solitary manifestation of a penile lesion in chronic lymphocytic leukemia.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tima DavidsonDepartment of Nuclear Medicine, Sheba Medical Center, Derech Sheba 2, 52621, Ramat Gan, Tel-Hashomer, Israel. Tima.Davidson@sheba.health.gov.il.
Liran DomachevskyDepartment of Nuclear Medicine, Sheba Medical Center, Derech Sheba 2, 52621, Ramat Gan, Tel-Hashomer, Israel.
Yogev GiladiSackler Faculty of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, Israel.
Eddie FridmanSackler Faculty of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, Israel.
Zohar DotanSackler Faculty of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, Israel.
Barak RosenzweigSackler Faculty of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, Israel.
Raya LeibowitzSackler Faculty of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, Israel.
Jennifer Ben ShimolSackler Faculty of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, Israel.
Tel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While penile metastases are rare, PET/CT has facilitated their detection. We aimed to describe penile secondary lesions (PSL) identified by PET/CT. We reviewed 18F-FDG and Ga68-PSMA PET/CT records performed in a single center during May 2012-March 2020, for PSL. Of 16,774 18F-FDG and 1,963 Ga68-PSMA-PET scans, PSL were found in 24(0.13%) men with a mean age of 74. PSMA detected PSL in 12 with prostate cancer; FDG identified PSL in 4 with lymphoma, 3 with colorectal cancer, 2 with lung cancer, and one each with bladder cancer, pelvic sarcoma, and leukemia. Mean SUVmax of PSL was 7.9 ± 4.2 with focal uptake in 13(54%). Mean lesion size was 16.5 ± 6.8 mm; 8 at the penile root, 4 along the shaft, and 1 at the glans. CT detected loss of the penile texture in 15(63%). PSL were observed only during relapse or follow-up of disseminated disease. Among those with prostate cancer, PSA varied widely. Fifteen (62.5%) died, at a mean 13.3 ± 15.9 months following PSL demonstration, nine had non-prostate malignancies. PET/CT identified and characterized PSL in a fraction of cancer patients, most commonly those with prostate cancer. PSL universally surfaced in advanced disease, and signaled high mortality, especially in non-prostate cancers.

Indexed as

Positron Emission Tomography Computed TomographyAgedAged, 80 and overBiomarkers, TumorBiopsyFluorodeoxyglucose F18HumansMaleMiddle AgedMultimodal ImagingPelvic NeoplasmsPenile NeoplasmsPositron-Emission TomographyProstatic NeoplasmsRetrospective StudiesTomography, X-Ray ComputedBiomarkers, TumorFluorodeoxyglucose F18

Identifiers

PMID33723317
PMCPMC7960694
OpenAlexW3137044965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.